Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.

Millar BC, Rendall JC, Downey DG, Moore JE.

J Clin Pharm Ther. 2018 Dec;43(6):836-843. doi: 10.1111/jcpt.12722. Epub 2018 Jun 29.

PMID:
29959786
2.

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00193-18. doi: 10.1128/JCM.00193-18. Print 2018 Sep.

3.

Occurrence of Pseudomonas aeruginosa in waters: implications for patients with cystic fibrosis (CF).

Caskey S, Stirling J, Moore JE, Rendall JC.

Lett Appl Microbiol. 2018 Jun;66(6):537-541. doi: 10.1111/lam.12876. Epub 2018 Apr 16.

PMID:
29537700
4.

In vitro activity of seven hospital biocides against Mycobacterium abscessus: Implications for patients with cystic fibrosis.

Caskey S, Moore JE, Rendall JC.

Int J Mycobacteriol. 2018 Jan-Mar;7(1):45-47. doi: 10.4103/ijmy.ijmy_197_17.

5.

Belfast Agar-a simple laboratory medium to separate Pseudomonas aeruginosa from pan-resistant Burkholderia cenocepacia isolated from the sputum of patients with cystic fibrosis (CF).

Caskey S, Moore JE, McCaughan J, Rendall JC.

Br J Biomed Sci. 2018 Apr;75(2):101-103. doi: 10.1080/09674845.2017.1411018. Epub 2018 Mar 7. No abstract available.

PMID:
29513134
6.

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.

Millar BC, McCaughan J, Rendall JC, Downey DG, Moore JE.

J Clin Pharm Ther. 2018 Feb;43(1):92-100. doi: 10.1111/jcpt.12616. Epub 2017 Sep 22.

PMID:
29293275
7.

Occurrence of Pseudomonas aeruginosa in taps: implications for patients with cystic fibrosis.

Caskey S, Stirling J, Moore JE, Rendall JC.

J Hosp Infect. 2018 Jan;98(1):64-65. doi: 10.1016/j.jhin.2017.10.018. Epub 2017 Oct 26. No abstract available.

PMID:
29107077
8.

MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Vallières E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG.

ERJ Open Res. 2016 Mar 15;2(1). pii: 00064-2015. eCollection 2016 Jan.

9.

How reliable are cough swabs for the detection of Pseudomonas aeruginosa in adult patients with cystic fibrosis?

Moore JE, McCaughan J, McNeilly J, Rendall JC, Downey DG.

Br J Biomed Sci. 2015;72(4):206. No abstract available.

PMID:
26738405
11.

Pseudomonas aeruginosa displays an altered phenotype in vitro when grown in the presence of mannitol.

Moore JE, Rendall JC, Downey DG.

Br J Biomed Sci. 2015;72(3):115-9.

PMID:
26510267
12.

Survival dynamics of cystic fibrosis-related Gram-negative bacterial pathogens (Pseudomonas aeruginosa and Burkholderia cenocepacia) in Dead Sea and Atlantic Ocean waters.

Shteinberg M, Kis-Papo T, Millar BC, Rendall JC, Downey DG, Elborn JS, Moore JE.

J Water Health. 2015 Sep;13(3):773-6. doi: 10.2166/wh.2015.157.

PMID:
26322762
13.

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis.

Kenny SL, Shaw TD, Downey DG, Moore JE, Rendall JC, Elborn JS.

BMJ Open Respir Res. 2014 Apr 23;1(1):e000021. doi: 10.1136/bmjresp-2014-000021. eCollection 2014.

14.

Do veterinary antibiotics have efficacy against highly resistant Gram-negative pathogens from patients with cystic fibrosis?

Moore JE, Alcorn M, Ara W, Millar BC, McCaughan J, Rendall JC, McNeilly J, Kuribayashi T, Yamamoto S, Matsuda M, Goldsmith CE, Elborn JS, Downey DG.

Int J Antimicrob Agents. 2015 Jan;45(1):93-5. doi: 10.1016/j.ijantimicag.2014.08.003. Epub 2014 Sep 6. No abstract available.

PMID:
25245210
16.

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.

Rao P, McCaughan J, McCalmont M, Goldsmith CE, Hall V, Millar BC, McCann MA, Downey DG, Rendall JC, Elborn JS, Moore JE.

J Cyst Fibros. 2012 Jul;11(4):349-52. doi: 10.1016/j.jcf.2012.01.002. Epub 2012 Feb 9. No abstract available.

17.

Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa.

Parkins MD, Rendall JC, Elborn JS.

Chest. 2012 Feb;141(2):485-493. doi: 10.1378/chest.11-0917. Epub 2011 Aug 11.

PMID:
21835906
18.

Lack of isolation of Pseudomonas aeruginosa associated with agricultural practices: relevance to patients with cystic fibrosis.

Moore JE, Maeda Y, Goldsmith CE, Millar BC, Rendall JC, Elborn JS, Moore PJ, Rao JR.

Br J Biomed Sci. 2011;68(1):45-7. No abstract available.

PMID:
21473263
19.

Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis.

Maeda Y, Murayama M, Goldsmith CE, Coulter WA, Mason C, Millar BC, Dooley JS, Lowery CJ, Matsuda M, Rendall JC, Elborn JS, Moore JE.

J Antimicrob Chemother. 2011 Mar;66(3):476-86. doi: 10.1093/jac/dkq485. Epub 2010 Dec 29.

PMID:
21193474
20.

Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF).

Maeda Y, Elborn JS, Parkins MD, Reihill J, Goldsmith CE, Coulter WA, Mason C, Millar BC, Dooley JS, Lowery CJ, Ennis M, Rendall JC, Moore JE.

J Cyst Fibros. 2011 Mar;10(2):133-9. doi: 10.1016/j.jcf.2010.11.003. Epub 2010 Dec 9.

21.

Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population.

Parkins MD, Parkins VM, Rendall JC, Elborn S.

Ther Adv Respir Dis. 2011 Apr;5(2):105-19. doi: 10.1177/1753465810386051. Epub 2010 Nov 15. Review.

PMID:
21078692
22.

Determination of optimum incubation time for release of bacteria from sputum of patients with cystic fibrosis using dithiothreitol (sputasol).

Mcclean M, Stanley T, Goldsmith CE, Millar BC, McClurg B, Elborn JS, Lowery CJ, Dooley JS, Rendall JC, Moore JE.

Br J Biomed Sci. 2010;67(2):89-91. No abstract available.

PMID:
20669768
23.

Molecular conservation within LES9F and PS21 liverpool epidemic strain (LES) markers in wild-type clinical pseudomonas aeruginosa isolated from the sputum of adult patients with cystic fibrosis.

Kakinuma Y, Goldsmith CE, Watt A, Elborn JS, Maeda Y, Rendall JC, Hall V, McCaughan J, Reid A, Millar BC, Matsuda M, Moore JE.

Br J Biomed Sci. 2010;67(2):87-8. No abstract available.

PMID:
20669766
24.

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).

Moore JE, Maeda Y, Goldsmith CE, Rendall JC, Elborn JS.

J Cyst Fibros. 2010 May;9(3):237-8. doi: 10.1016/j.jcf.2010.03.005. Epub 2010 Apr 7. No abstract available.

25.

Do equine strains of Pseudomonas aeruginosa carry the Liverpool epidemic strain markers relevant to patients with cystic fibrosis?

Tazumi A, Maeda Y, Goldsmith CE, Millar BC, Rendall JC, Elborn JS, Buckley T, Matsuda M, Moore JE.

Br J Biomed Sci. 2010;67(1):30-1. No abstract available.

PMID:
20373680
26.

CD18 dependency of transendothelial neutrophil migration differs during acute pulmonary inflammation.

Mackarel AJ, Russell KJ, Ryan CM, Hislip SJ, Rendall JC, FitzGerald MX, O'Connor CM.

J Immunol. 2001 Sep 1;167(5):2839-46.

Supplemental Content

Loading ...
Support Center